Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00027404
Other study ID # FD-R-2026-01
Secondary ID FD-R-002026-01
Status Completed
Phase N/A
First received December 5, 2001
Last updated March 24, 2015
Start date September 2001
Est. completion date August 2005

Study information

Verified date November 2002
Source FDA Office of Orphan Products Development
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.


Description:

Eligible patients will undergo comprehensive evaluation. Informants familiar with the patient will also provide information. Patients will be randomized to receive treatment or placebo. During the 12-week treatment there will be weekly monitoring for the first 4 weeks and biweekly monitoring for the next 8 weeks. The drug dosage will be increased each week as tolerated by the patient. Serum levels of fluoxetine and norfluoxetine will be documented at Week 12.

Completion date provided represents the completion date of the grant per OOPD records


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date August 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion criteria:

- Meets DSM-IV and ADI criteria for autistic disorder

- Patients must use effective contraception

- Negative pregnancy test

- Clinical Global Impression-Severity Scale for Autistic Disorder (CGI-AD) score of 4

Exclusion criteria:

- Pregnant or nursing

- Prior or concurrent history of mental disorders, including schizophrenia, schizoaffective disorder, organic mental disorders, or bipolar disorders

- Concurrent depression determined by DSM-IV diagnosis

- Serious suicidal risk

- Active seizure disorder within the past 2 years

- Clinically significant or unstable medical illness, including hematopoietic or cardiovascular disease

- Any organic or systemic disease

- Any geographical condition that would preclude study compliance

- Prior or concurrent gastrointestinal, liver, or kidney disease

- Any other concurrent condition that interferes with the absorption, distribution, metabolism, or excretion of drugs

- Prior or concurrent cerebrovascular disease or brain trauma

- Prior or concurrent clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism

- Prior or concurrent malignancy

- Clinically significant abnormalities on EKG, laboratory tests, or physical exam

- Requirement for ECT or any other psychotropic medication

- Inability to tolerate taper from psychoactive medication

- History of hypersensitivity or severe side effects associated with the use of fluoxitine or other serotonin reuptake inhibitors

- Treatment with any drug known to have a well-defined potential for toxicity to a major organ within the past 30 days

- Concurrent terfenadine (Seldane) or astemizole (Hismanal)

- Prior treatment with fluoxetine of 40 mg/day for 6 weeks

- Prior electroconvulsive therapy within the past 3 months

- Prior investigational drug use within the past 30 days

- Prior Monoamine oxidase inhibitor use within the past 14 days

- Prior long-acting phenothiazines within the past 6 weeks

- Prior psychotropic drugs within the past 7 days

- Prior fluoxetine within the past 6 weeks

- Requirement for any therapeutic intervention that would confound study evaluation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fluoxetine


Locations

Country Name City State
United States Mount Sinai School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT02568631 - Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls N/A
Completed NCT02708290 - Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Completed NCT02369445 - Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention N/A
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01617460 - A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder Phase 3
Completed NCT01400269 - An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism N/A
Active, not recruiting NCT02442115 - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Completed NCT00926471 - Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders Phase 1
Completed NCT00692315 - Treating Oxidative Stress in Children With Autism N/A
Completed NCT00365859 - Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Phase 3
Completed NCT00198107 - Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism Phase 3
Completed NCT00095420 - Relationship Training for Children With Autism and Their Peers N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT04820998 - Living in a Precarious Situation With an Autistic Child: What Are the Issues at Stake for Support in Care
Withdrawn NCT05413187 - A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder Phase 2
Recruiting NCT02275455 - Design Of WELL Being Monitoring Systems, Application in Autism N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT01977248 - Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12 N/A
Terminated NCT01592773 - Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2